Article Text

PDF
S112 Long-term safety and efficacy of ivacaftor in pediatric patients aged 2-5 years with cystic fibrosis and a cftr gating mutation

Abstract

JC Davies has served on advisory boards, undertaken educational activities, and served as national/site principal investigator for trials, for which her institution has received funding from Vertex Pharmaceuticals Incorporated.

S Robertson is an employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company.

J Cooke is an employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company.

M Higgins is an employee of Vertex Pharmaceuticals Incorporated and my own stock or stock options in that company.

M Rosenfeld: has served as a national and site investigator for trials and as a consultant, for which her institution received funding from Vertex Pharmaceuticals Incorporated.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.